Search Results for “AstraZeneca” – Page 27 – media

Boehringer, Vanderbilt U to develop cancer MCL1 inhibitors in third team-up

Cancer cells are different from normal cells in that they can avoid a naturally programmed cell death process known as apoptosis and grow almost indefinitely. In their third collaboration, Boehringer Ingelheim and Vanderbilt University have their eyes on a target that helps cancer cells evade death.
- Source: fiercebiotech
- 447
- March 16, 2018
apoptosis Company Insight MCL1
Merck and Eisai Ink $5.76B Cancer Deal

Merck & Company and Tokyo-based Eisai Inc. have signed a strategic collaboration deal to develop and commercialize Lenvima (lenvatinib mesylate) with Merck’s anti-PD-1 drug Keytruda (pembrolizumab).
- Source: Biospace
- 508
- March 12, 2018
keytruda LENVIMA Market Views
First European filing acceptance of a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in type-1 diabetes

AstraZeneca today announced that the European Medicines Agency has accepted the Marketing Authorisation Variation forForxiga (dapagliflozin), a selective SGLT-2 inhibitor, for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).
- Source: astrazeneca
- 671
- March 7, 2018
AstraZeneca diabetes Forxiga insulin New Approvals
Viela Bio Spins Out of MedImmune; Raises Up to $250 Million in Series A Financing, 6 Dimensions Capital Leads Investment

Viela Bio announced today that it has incorporated as an independent, inflammation - and autoimmunity - focused biotechnology company after spinning out from MedImmune, the global biologics research and development arm of AstraZeneca. Viela Bio will primarily focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of the diseases.
- Source: finance.yahoo
- 475
- March 1, 2018
autoimmunity inflammation Market Views
Bay Area’s Rani Therapeutics Lands $53M as Company Moves to Clinical Trials

Rani Therapeutics scored $53 million in financing to take its oral pill designed to replace injectable drug delivery for chronic disease treatment into clinical trials.
- Source: Biospace
- 473
- February 28, 2018
chronic diseases Company Insight oral pill
AZ/MSD’s Lynparza wins new CHMP nod

AstraZeneca and MSD’s Lynparza is a step closer to being cleared in Europe as maintenance therapy for some patients with ovarian cancer.
- Source: pharmatimes
- 543
- February 28, 2018
AstraZeneca Chemotherapy MSD New Approvals ovarian cancer
Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2017.
- Source: Merck
- 518
- February 19, 2018
Company Insight Merck
Global Investors Back Rani Therapeutics With $53 Million As Company Moves To Clinical Trials

Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, today announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials. This investment brings the total raised to $142 million in funding.
- Source: Prnewswire;
- 517
- February 13, 2018
chronic diseases Clinical Trials Series
CRISPR CSO departs as Celgene continues to sell stock

Bill Lundberg, M.D., has stepped down as CSO of CRISPR Therapeutics. News of Lundberg’s departure emerged on the same day Celgene revealed it has sold another chunk of its once-double-digit stake in the CRISPR/Cas9 gene editing startup.
- Source: fiercebiotech
- 546
- February 12, 2018
Celgene CRISPR Market Views
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

The commercial life for Novartis’ Arzerra outside the U.S. is coming to an end.
- Source: Fiercepharma
- 543
- January 25, 2018
Arzerra CLL Company Insight

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.